Skip to main content

Edwards Lifesciences Corp guidance

  • EW · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$107.11−0.04%Close 16 Nov 2026 · Market value $61.54B

In its results release of 4 Nov 2026 (Q3 FY2026), Edwards Lifesciences Corp gave 1 forecast in figures, among them revenue of $1.67B to $1.75B for Q4 FY2026. Over the last two years, results landed above the company's own last range 6 of 12 times, within it 6 and below it 0.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 4 Nov 2026

MeasurePeriodGuidanceAs stated
RevenueQ4 FY2026$1.67B to $1.75BFor the fourth quarter of 2026, the company projects total sales to be between $1.67 and $1.75 billion and adjusted EPS of $0.61 to $0.69.

Source: the company's earnings release.

Guidance against results above 6 · within 6 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
Organic revenue growthFY2026+10% to +11%Given once—To come
EPS · AdjustedFY2026$2.95 to $3.05Given once—To come
EPS growth · AdjustedFY2026+17%Given once—To come
RevenueFY2026$6.60B to $6.90BRaised once—To come
Organic revenue growthFY2026+9% to +11%Given once—To come
EPS · AdjustedFY2026$2.95 to $3.05Raised once—To come
EPSFY2026$2.90 to $3.05Given once—To come
Gross margin · AdjustedFY202678% to 79%Given once—To come
RevenueQ4 FY2026$1.67B to $1.75BGiven once—To come
RevenueQ2 FY2026$1.66B to $1.74BGiven once$1.74BWithin the range
EPS · AdjustedQ2 FY2026$0.70 to $0.76Given once$0.78Above the range
RevenueQ1 FY2026$1.55B to $1.63BGiven once$1.65BAbove the range
EPS · AdjustedQ1 FY2026$0.70 to $0.76Given once$0.78Above the range
RevenueFY2025$5.90B to $6.10BRaised once$6.07BWithin the range
Revenue growthFY2026+9% to +10%Unchanged+11.55%Above the range
RevenueQ4 FY2025$1.51B to $1.59BGiven once$1.57BWithin the range
EPS · AdjustedQ4 FY2025$0.58 to $0.64Given once$0.58Within the range
RevenueQ3 FY2026$1.46B to $1.54BGiven once$1.55BAbove the range
EPS · AdjustedQ3 FY2026$0.54 to $0.60Given once$0.67Above the range
RevenueQ2 FY2025$1.45B to $1.53BGiven once$1.53BAbove the range
RevenueQ1 FY2025$1.35B to $1.43BGiven once$1.41BWithin the range
RevenueQ4 FY2024$1.33B to $1.39BGiven once$1.39BWithin the range

EW in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.